Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.

Nick Colangelo, President and CEO will present at the CG MedTech, Diagnostics, and Digital Health & Service Forum at 10:00 a.m. ET on Thursday, November 17, 2022. Joe Mara, CFO will also present on Thursday, November 17, 2022 at 11:00 a.m. ET at the Stephens Annual Investment Conference.

Webcasts of both presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact:
Julie Downs
media@vcel.com

Staff

Recent Posts

FendX Provides Shareholder Update

Oakville, Ontario--(Newsfile Corp. - April 7, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

56 minutes ago

Lenire Supports Veterans by Sponsoring Hearoes Tour

Lenire proudly sponsors the 10th Annual LexCare Hearing Foundation Hearoes Tour.Lenire is a treatment option…

56 minutes ago

Millions of people unite around doing good on the 19th International Good Deeds Day held yesterday worldwide

Good Deeds Day continues to expand worldwide, as the peak event of year-round volunteer activities.…

56 minutes ago

Philips Applauded by Frost & Sullivan for Improving Imaging Quality and Efficiency in Healthcare with Its CT 3500 Imaging Solution

Philips CT 3500, a scalable, adaptable, and durable imaging solution, improves efficiency and care quality,…

7 hours ago

LG EXPANDS MENTAL HEALTH SUPPORT FOR NCAA FINAL FOUR HOST SCHOOLS WITH NAMI PARTNERSHIP

LG continues its commitment to supporting mental health awareness, providing resources and support for students…

19 hours ago

Scarless MTF Breast Augmentation Performed by Seattle Plastic Surgeon

Dr. Sajan Delivers Natural-Looking Transgender Breast Augmentation Without Chest ScarsSEATTLE, April 05, 2025 (GLOBE NEWSWIRE)…

22 hours ago